Compare CVE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | BDX |
|---|---|---|
| Founded | 2009 | 1897 |
| Country | Canada | United States |
| Employees | 8300 | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0B | 43.0B |
| IPO Year | N/A | 1997 |
| Metric | CVE | BDX |
|---|---|---|
| Price | $24.65 | $158.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $30.50 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 8.1M | 2.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | 2.03% | ★ 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.74 | $3.02 |
| P/E Ratio | ★ $18.07 | $632.44 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $13.86 | $140.11 |
| 52 Week High | $32.07 | $213.08 |
| Indicator | CVE | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 62.95 |
| Support Level | $23.74 | $153.27 |
| Resistance Level | $30.47 | $159.79 |
| Average True Range (ATR) | 0.65 | 3.98 |
| MACD | -0.15 | 1.29 |
| Stochastic Oscillator | 8.14 | 96.56 |
Cenovus Energy Inc is a Canadian integrated energy group. The group's upstream operations include oil sands projects in northern Alberta; thermal and conventional crude oil, natural gas, and natural gas liquids (NGLs) projects across Western Canada; crude oil production offshore Newfoundland and Labrador; and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada. The group's reportable segments are: Oil Sands, Conventional, Offshore, Canadian Refining, U.S Refining, and Corporate and Eliminations. Maximum revenue is generated from its Oil Sands segment. Geographically, the group derives maximum revenue from the U.S., followed by Canada and China.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.